33 results about "Fibrosarcoma" patented technology

Methods of treating a fibrosacroma using flt-3 ligand are disclosed, as well as methods of increasing the number of dendritic cells in a patient having a fibrosarcoma.

The invention relates to treatment of cancer. More specifically the invention relates to methods of treating cancer selected from the group consisting of squamous cell cancer, lung cancer including small-cell lung cancer, non-small cell lung cancer, adenocarcinoma of the lung, and squamous carcinoma of the lung, cancer of the peritoneum, hepatocellular cancer, gastric or stomach cancer including gastrointestinal cancer, pancreatic cancer, glioblastoma, cervical cancer, ovarian cancer, liver cancer, bladder cancer, hepatoma, breast cancer, colon cancer, colorectal cancer, endometrial or uterine carcinoma, salivary gland carcinoma, kidney or renal cancer, liver cancer, prostate cancer, vulval cancer, thyroid cancer, hepatic carcinoma and various types of head and neck cancer, as well as B-cell lymphoma including low grade / follicular non-Hodgkin's lymphoma (NHL); small lymphocytic (SL) NHL; intermediate grade / follicular NHL; intermediate grade diffuse NHL; high grade immunoblastic NHL; high grade lymphoblastic NHL; high grade small non-cleaved cell NHL; bulky disease NHL; mantle cell lymphoma; AIDS-related lymphoma; and Waldenstrom's Macroglobulinemia; chronic lymphocytic leukemia (CLL); acute lymphoblastic leukemia (ALL); Hairy cell leukemia; chronic myeloblastic leukemia; and post-transplant lymphoproliferative disorder (PTLD), as well as abnormal vascular proliferation associated with phakomatoses, edema such as that associated with brain tumors, Meigs' syndrome, melanoma, mesothelioma, multiple myeloma, fibrosarcoma, osteosarcoma and epidermoid carcinoma, by administering antibodies directed to α2β1 integrin.

Compositions and methods are provided that relate to an attenuated reovirus exhibiting oncolytic activity toward cancer cells while displaying reduced lytic activity toward non-malignant cells. Exemplified is an attenuated human reovirus derived from persistently infected fibrosarcoma cells that lacks wild-type reovirus S1 and S4 genes and consequently lacks a detectable reoviral outer capsid .sigma.1 protein and expresses a mutated reoviral outer capsid .sigma.3 protein.

Compositions and methods are provided that relate to an attenuated reovirus exhibiting oncolytic activity toward cancer cells while displaying reduced lytic activity toward non-malignant cells. Exemplified is an attenuated human reovirus derived from persistently infected fibrosarcoma cells that lacks wild-type reovirus S1 and S4 genes and consequently lacks a detectable reoviral outer capsid σ1 protein and expresses a mutated reoviral outer capsid σ3 protein.

The invention discloses an amino acid positron emission tomography (PET) imaging agent, and a preparation method and application thereof. The imaging agent belongs to the field of N-substituted positron nuclide labeled glutamic acid compound and has a structure as shown in the specification; and the L*represents -11CH3, CH2CH218F, and -COCH (18F) CH3. The novel imaging agent N-(2-18F-fluoropropionyl)-glutamic acid shows good tumor PET imaging sensitivity and specificity, has high uptake on tumor (such as S180 fibrosarcoma), and no obvious uptake on other tissues and organs (except for bladder) in the body, and indicates high tumor to background ratio. In vitro-in vivo experiments show that N-(2 - 18F -fluoropropionyl)-glutamic acid is stable in vitro and in vivo and shows good pharmacokinetic properties.

The present invention relates to the use of a nucleic acid that comprises a sequence encoding an APOBEC3A protein, in preventing or treating a tumor in a patient.

The invention discloses an application of miltipolone or pharmaceutically acceptable salts thereof in the preparation of medicines for preventing or curing diseases related to Fe2+. A cancer cell inhibiting effect of the medicines prepared by the miltipolone or the pharmaceutically acceptable salts thereof realizes the purpose of anticancer through inhibiting cancer cell proliferation ; and particularly, the invention provides new choices of the medicines for curing or preventing human lung cancer, human liver cancer, human cervical carcinoma, human breast carcinoma, leukocythemia, fibrosarcoma, or gastric cancer.

The invention provides new application of valeriana jatamansi jones total flavonoids, in particular application in preparing a medicament for treating liver cancer or fibrosarcoma. The invention also provides a medicinal composition for treating liver cancer or fibrosarcoma. The valeriana jatamansi jones total flavonoids have remarkable inhibiting effect on the growth of tumors in mice inoculatedwith liver cancer H22 and fibrosarcoma S180 so as to show that the valeriana jatamansi jones total flavonoids have obvious effect of resisting the liver cancer and the fibrosarcoma and provide a new medicament selection for clinic.